Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1740-1746

  Brown, Ashley N ^a   McSharry, James J ^a   Weng, Qingmei ^a   Adams, Jonathan R ^a   Kulawy, Robert ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPERIMENTAL INFECTION; HOLLOW FIBER; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYCLOPENTANES; DOGS; DRUG RESISTANCE, VIRAL; GUANIDINES; INFLUENZA A VIRUS, H1N1 SUBTYPE; OSELTAMIVIR; ZANAMIVIR;

EID: 79953185751     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01628-10     Document Type: Article

References (56)

1. Balter, S., L. S. Gupta, S. Lim, J. Fu, and S. E. Perlman for the New York City 2009 H1N1 Flu Investigation Team. 2010. Pandemic (H1N1) 2009 surveillance for severe illness, New York, New York, USA, April-July 2009. Emerg. Infect. Dis. 16:1259-1264.
2. Bautista, E., et al. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362:1708-1719.
3. Birnkrant, D., and E. Cox. 2009. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 361:2204-2207.
4. Brown, A. N., et al. 2011. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob. Agents Chemother. 55:1747-1753.
5. Brown, A. N., et al. 2010. In vitro system for modeling influenza A virus resistance under drug pressure. Antimicrob. Agents Chemother. 54:3442-3450.
6. Calfee, D. P., A. W. Peng, L. M. Cass, M. Lobo, and F. G. Hayden. 1999. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43:1616-1620.
7. CDC. 2010. FluView: 2009-2010 influenza season week 16 ending April 24, 2010. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/flu/weekly/.
8. CDC. 2009. Update: influenza activity-United States, September 28, 2008-April 4, 2009, and composition of the 2009-2010 influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 58:369-374.
9. Chowell, G., et al. 2009. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N. Engl. J. Med. 361:674-679.
10. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
11. Dawood, F. S., et al. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360:2605-2615.
12. Deyde, V. M., et al. 2010. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob. Agents Chemother. 54:1102-1110.
13. Dharan, N. J., et al. 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
14. Domínguez-Cherit, G., et al. 2009. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 302:1880-1887.
15. Dulek, D. E., et al. 2010. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin. Infect. Dis. 50:1493-1496.
16. Esposito, S., et al. 2010. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J. Clin. Virol. 48:62-65.
17. Fraser, C., et al. 2009. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324:1557-1561.
18. Furuta, Y., et al. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49:981-986.
19. Garten, R. J., et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 325: 197-201.
20. Gaur, A. H., et al. 2010. Intravenous zanamivir for oseltamivir resistant 2009 H1N1 influenza. N. Engl. J. Med. 362:88-89.
21. GlaxoSmithKline. 2009. Zanamivir investigator's brochure. GlaxoSmithKline, Research Triangle Park, NC.
22. Gooskens, J., et al. 2009. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A (H1N1) virus. JAMA 301:1042-1046.
23. Halasa, N. B. 2010. Update on the 2009 pandemic influenza A H1N1 in children. Curr. Opin. Pediatr. 22:83-87.
24. Härter, G., et al. 2010. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin. Infect. Dis. 50:1249-1251.
25. Hayden, F., et al. 2000. Inhaled zanamivir for the prevention of influenza in families. N. Engl. J. Med. 343:1282-1289.
26. Hedlund, M., L. M. Aschenbrenner, K. Jansen, J. L. Larson, and F. Fang. 2010. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J. Infect. Dis. 201:1007-1015.
27. Hurt, A. C., J. K. Holien, M. Parker, A. Kelso, and I. G. Barr. 2009. Zanamivir-resistant influenza virus with a novel neuraminidase mutation. J. Virol. 83:10366-10373.
28. Itoh, Y., et al. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
29. Jain, S., et al. 2009. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N. Engl. J. Med. 361:1935-1944.
30. Kati, V. M., et al. 2002. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 46:1014-1021.
31. Kilbourne, E. D. 2006. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 12:9-14.
32. Kubo, S., T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita. 2010. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother. 54:1256-1264.
33. Kumar, A., et al. 2009. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 302:1872-1879.
34. Lapinsky, S. E. 2010. Epidemic viral pneumonia. Curr. Opin. Infect. Dis. 23:139-144.
35. Libster, R., et al. 2010. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N. Engl. J. Med. 362:45-55.
36. Louie, J. K., M. Acosta, D. J. Jamieson, and M. A. Honein for the California Pandemic (H1N1) Working Group. 2010. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N. Engl. J. Med. 362:27-35.
37. Malakhov, M. P., et al. 2006. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 50:1470-1479.
38. McSharry, J. J., Q. Weng, A. N. Brown, R. Kulawy, and G. L. Drusano. 2009. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 53:2375-2381.
39. Memoli, M. J., R. J. Hrabal, A. Hassantoufighi, M. C. Eichelberger, and J. K. Taubenberger. 2010. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin. Infect. Dis. 50:1252-1255.
40. Memoli, M. J., et al. 2010. Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host. J. Infect. Dis. 201:1397-1403.
41. Metzgar, D., et al. 2010. Initial identification and characterization of an emerging zoonotic influenza virus prior to pandemic spread. J. Clin. Microbiol. 48:4228-4234.
42. Molla, A., et al. 2002. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J. Virol. 76:5380-5386.
43. Moscona, A. 2005. Oseltamivir resistance - disabling our influenza defenses. N. Engl. J. Med. 353:2633-2636.
44. Negovetich, N. J., and R. G. Webster. 2010. Thermostability of subpopulations of H2N3 influenza virus isolates from mallard ducks. J. Virol. 84:9369-9376.
45. Nguyen, J. T., et al. 2009. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 53:4115-4126.
46. Nguyen, J. T., et al. 2010. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5:e9332.
47. Perez-Padilla, R., et al. 2009. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med. 361:680-689.
48. Sleeman, K., et al. 2010. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54:2517-2524.
49. Smee, D. F., J. H. Huffman, A. C. Morrison, D. L. Barnard, and R. W. Sidwell. 2001. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45:743-748.
50. Smee, D. F., et al. 2010. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 88:38-44.
51. Stephenson, I., et al. 2009. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin. Infect. Dis. 48:389-396.
52. Sugaya, N., and Y. Ohashi. 2010. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 54:2575-2582.
53. Torres, J. P., et al. 2010. Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile. Clin. Infect. Dis. 50:860-868.
54. Viboud, C., M. Miller, D. Olson, M. Osterholm, and L. Simonsen. 20 March 2010. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PloS Curr. 2010:RRN1153.
55. World Health Organization. 10 October 2009.DGstatement following the meeting of the Emergency Committee. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/swineflu/4th-meeting-ihr/en/index. html.
56. Zepeda, H. M., et al. 2010. Identification of influenza A pandemic (H1N1) 2009 variants during the first 2009 influenza outbreak in Mexico City. J. Clin. Virol. 48:36-39.